Silverarc Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Silverarc Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.8M	Sell	1,108,295 -893,745	-45%	-$16.9M	2.79%	9
2026 Q1	$32.9M	Buy	2,002,040 +972,974	+95%	+$18.6M	3.36%	10
2025 Q4	$16.1M	Buy	1,029,066 +334,124	+48%	+$4.5M	2.24%	13
2025 Q3	$5.15M	Buy	+694,942	New	+$3.68M	0.69%	41
2023 Q3	–	Sell	-31,156	Closed	-$213K	–	89
2023 Q2	$213K	Hold	31,156	–	–	0.07%	75
2023 Q1	$243K	Buy	+31,156	New	+$217K	0.1%	67

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management's GLUE Position: Q2 2026 in Review

Silverarc Capital Management reduced its Monte Rosa Therapeutics (GLUE) stake by 45% in Q2 2026, selling an estimated $16.9M and leaving 1,108,295 shares worth $26.8M. The position accounts for 2.79% of the portfolio, ranked #9.

Silverarc Capital Management first reported a position in GLUE in Q1 2023 and has held it in 6 quarters since. The position peaked at $32.9M in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

Silverarc Capital Management held 1,108,295 shares of Monte Rosa Therapeutics worth $26.8M as of Q2 2026.
Silverarc Capital Management sold 893,745 Monte Rosa Therapeutics shares in Q2 2026, an estimated $16.9M.
Monte Rosa Therapeutics made up 2.79% of Silverarc Capital Management's portfolio in Q2 2026, its #9 holding.
Silverarc Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 6 quarters since.
Silverarc Capital Management's Monte Rosa Therapeutics position peaked at $32.9M in Q1 2026.
193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.